Antitumor activity of a novel small molecule TLR7 agonist via immune response induction and tumor microenvironment modulation

Diao,Yuwen; Wang,Xiaodong; Wan,Yanyan; Zhong,Jingjing; Gao,Dong; Liu,Yu; Gao,Ningning; Li,Wang; Liu,Bing; Huang,Xinping; Jin,Zhenchao; Peng,Boya; Wang,Zhulin; Fu,Li; Chen,Siping; Jin,Guangyi

doi:10.3892/or.2015.4436

Antitumor activity of a novel small molecule TLR7 agonist via immune response induction and tumor microenvironment modulation

Authors:
- Yuwen Diao
- Xiaodong Wang
- Yanyan Wan
- Jingjing Zhong
- Dong Gao
- Yu Liu
- Ningning Gao
- Wang Li
- Bing Liu
- Xinping Huang
- Zhenchao Jin
- Boya Peng
- Zhulin Wang
- Li Fu
- Siping Chen
- Guangyi Jin
View Affiliations

Affiliations: Cancer Research Center, National‑Regional Key Technology Engineering Laboratory for Medical Ultrasound, School of Medicine, Shenzhen University, Shenzhen, Guangdong 518060, P.R. China
Published online on: November 18, 2015 https://doi.org/10.3892/or.2015.4436
Pages: 793-800

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Immunotherapy is emerging as a powerful and active tumor-specific approach against cancer via triggering the immune system. Toll-like receptors (TLRs) are fundamental elements of the immune system, which facilitate our understanding of the innate and adaptive immune pathways. TLR agonists used as single agents can effectively eradicate tumors due to their potent stimulation of innate and adaptive immunity. We examined the effects of a novel adenine type of TLR7 agonists on both innate and adaptive immune activation in vitro and in vivo. We established the local and distant tumor‑bearing mice derived from murine mammary carcinoma cell line (4T1) to model metastatic disease. Our data demonstrated that SZU101 was able to stimulate innate immune cells to release cytokines at the very high level compared with LPS at the same or lower concentration. Locally intratumoral SZU101 injection can elicit a systemic antitumor effect on murine breast tumor model. SZU101 affected the frequency of intratumoral immune cell infiltration, including the percentage of CD4+ and CD8+ increase, and the ratio of Tregs decrease. Our data reveal that the antitumor effect of SZU101 is associated with multiple mechanisms, inducing tumor‑specific immune response, activation of innate immune cells and modulation of the tumor microenvironment.

View Figures

View References

1	Barton GM and Medzhitov R: Toll-like receptors and their ligands. Curr Top Microbiol Immunol. 270:81–92. 2002.PubMed/NCBI
2	Iwasaki A and Medzhitov R: Toll-like receptor control of the adaptive immune responses. Nat Immunol. 5:987–995. 2004. View Article : Google Scholar : PubMed/NCBI
3	Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, Oesterich JL, Gorden KB, Qiu X, McKane SW, et al: Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 218:74–86. 2002. View Article : Google Scholar : PubMed/NCBI
4	van Duin D, Medzhitov R and Shaw AC: Triggering TLR signaling in vaccination. Trends Immunol. 27:49–55. 2006. View Article : Google Scholar
5	Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z, et al: Toll-like receptors in tumor immunotherapy. Clin Cancer Res. 13:5280–5289. 2007. View Article : Google Scholar : PubMed/NCBI
6	Adams S: Toll-like receptor agonists in cancer therapy. Immunotherapy. 1:949–964. 2009. View Article : Google Scholar
7	Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, Madsen CS, Cohen PA, Gendler SJ and Boons GJ: Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci USA. 109:261–266. 2012. View Article : Google Scholar :
8	Hurwitz AA and Watkins SK: Immune suppression in the tumor microenvironment: A role for dendritic cell-mediated tolerization of T cells. Cancer Immunol Immunother. 61:289–293. 2012. View Article : Google Scholar : PubMed/NCBI
9	Cheng C, Qu QX, Shen Y, Lv YT, Zhu YB, Zhang XG and Huang JA: Overexpression of B7-H4 in tumor infiltrated dendritic cells. J Immunoassay Immunochem. 32:353–364. 2011. View Article : Google Scholar : PubMed/NCBI
10	Jochems C and Schlom J: Tumor-infiltrating immune cells and prognosis: The potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood). 236:567–579. 2011. View Article : Google Scholar
11	Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Henrik Ter, Meulen J, Zitvogel L, Kroemer G, et al: Trial Watch: Toll-like receptor agonists in oncological indications. OncoImmunology. 3:e291792014. View Article : Google Scholar : PubMed/NCBI
12	Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K and Akira S: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 3:196–200. 2002. View Article : Google Scholar : PubMed/NCBI
13	Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, Raz E and Cottam HB: Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7. Proc Natl Acad Sci USA. 100:6646–6651. 2003. View Article : Google Scholar : PubMed/NCBI
14	Stary G, Bangert C, Tauber M, Strohal R, Kopp T and Stingl G: Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med. 204:1441–1451. 2007. View Article : Google Scholar : PubMed/NCBI
15	Zhu J, He S, Du J, Wang Z, Li W, Chen X, Jiang W, Zheng D and Jin G: Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma. J Hematol Oncol. 8:212015. View Article : Google Scholar : PubMed/NCBI
16	Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD and Allison JP: Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 6:226ra322014. View Article : Google Scholar : PubMed/NCBI
17	Stewart TJ and Smyth MJ: Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev. 30:125–140. 2011. View Article : Google Scholar : PubMed/NCBI
18	Kanzler H, Barrat FJ, Hessel EM and Coffman RL: Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med. 13:552–559. 2007. View Article : Google Scholar : PubMed/NCBI
19	Stojanovic A and Cerwenka A: Natural killer cells and solid tumors. J Innate Immun. 3:355–364. 2011. View Article : Google Scholar : PubMed/NCBI
20	Whiteside TL: Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol. 16:3–15. 2006. View Article : Google Scholar
21	Marcus A, Gowen BG, Thompson TW, Iannello A, Ardolino M, Deng W, Wang L, Shifrin N and Raulet DH: Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol. 122:91–128. 2014. View Article : Google Scholar : PubMed/NCBI
22	Cho D1, Shook DR, Shimasaki N, Chang YH, Fujisaki H and Campana D: Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res. 16:3901–3909. 2010. View Article : Google Scholar : PubMed/NCBI
23	Moreno M, Mol BM, von Mensdorff-Pouilly S, Verheijen RH, von Blomberg BM, van den Eertwegh AJ, Scheper RJ and Bontkes HJ: Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Cancer Lett. 272:70–76. 2008. View Article : Google Scholar : PubMed/NCBI
24	Lauzon NM, Mian F, MacKenzie R and Ashkar AA: The direct effects of Toll-like receptor ligands on human NK cell cytokine production and cytotoxicity. Cell Immunol. 241:102–112. 2006. View Article : Google Scholar : PubMed/NCBI
25	Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM and Ugolini S: Innate or adaptive immunity? The example of natural killer cells. Science. 331:44–49. 2011. View Article : Google Scholar : PubMed/NCBI
26	Chanmee T, Ontong P, Konno K and Itano N: Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel). 6:1670–1690. 2014. View Article : Google Scholar
27	Mosser DM and Edwards JP: Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 8:958–969. 2008. View Article : Google Scholar : PubMed/NCBI
28	Ostuni R, Kratochvill F, Murray PJ and Natoli G: Macrophages and cancer: From mechanisms to therapeutic implications. Trends Immunol. 36:229–239. 2015. View Article : Google Scholar : PubMed/NCBI
29	Lopez-Castejón G, Baroja-Mazo A and Pelegrín P: Novel macrophage polarization model: From gene expression to identification of new anti-inflammatory molecules. Cell Mol Life Sci. 68:3095–3107. 2011. View Article : Google Scholar
30	Ullrich E, Ménard C, Flament C, Terme M, Mignot G, Bonmort M, Plumas J, Chaperot L, Chaput N and Zitvogel L: Dendritic cells and innate defense against tumor cells. Cytokine Growth Factor Rev. 19:79–92. 2008. View Article : Google Scholar
31	Singh M, Khong H, Dai Z, Huang XF, Wargo JA, Cooper ZA, Vasilakos JP, Hwu P and Overwijk WW: Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol. 193:4722–4731. 2014. View Article : Google Scholar : PubMed/NCBI
32	Mao Y, Keller ET, Garfield DH, Shen K and Wang J: Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev. 32:303–315. 2013. View Article : Google Scholar
33	Diederichsen AC, Hjelmborg J, Christensen PB, Zeuthen J and Fenger C: Prognostic value of the CD4⁺/CD8⁺ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother. 52:423–428. 2003. View Article : Google Scholar : PubMed/NCBI
34	Broomfield SA, van der Most RG, Prosser AC, Mahendran S, Tovey MG, Smyth MJ, Robinson BW and Currie AJ: Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol. 182:5217–5224. 2009. View Article : Google Scholar : PubMed/NCBI
35	Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S and Katoh H: Concurrent infiltration by CD8⁺ T cells and CD4⁺ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 94:275–280. 2006. View Article : Google Scholar : PubMed/NCBI
36	Reissfelder C, Stamova S, Gossmann C, Braun M, Bonertz A, Walliczek U, Grimm M, Rahbari NN, Koch M, Saadati M, et al: Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J Clin Invest. 125:739–751. 2015. View Article : Google Scholar : PubMed/NCBI
37	Yamaguchi T and Sakaguchi S: Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol. 16:115–123. 2006. View Article : Google Scholar
38	Wang C, Zhou Q, Wang X, Wu X, Chen X, Li J, Zhu Z, Liu B and Su L: The TLR7 agonist induces tumor regression both by promoting CD4⁺ T cells proliferation and by reversing T regulatory cell-mediated suppression via dendritic cells. Oncotarget. 6:1779–1789. 2015. View Article : Google Scholar : PubMed/NCBI
39	Nelson D, Fisher S and Robinson B: The 'Trojan Horse' approach to tumor immunotherapy: Targeting the tumor microenvironment. J Immunol Res. 2014:7890692014. View Article : Google Scholar
40	Van der Jeught K, Bialkowski L, Daszkiewicz L, Broos K, Goyvaerts C, Renmans D, Van Lint S, Heirman C, Thielemans K and Breckpot K: Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget. 6:1359–1381. 2015. View Article : Google Scholar : PubMed/NCBI